Clinical Trials in Barcelona, Barcelona [Barcelona]
54 recruiting
Showing 1–20 of 49 trials
Recruiting
Phase 2
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
Lupus Erythematosus, SystemicLupus Nephritis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company89 enrolled93 locationsNCT07015983
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Breast CancerLung Cancer
Bristol-Myers Squibb416 enrolled64 locationsNCT06618287
Recruiting
Phase 2Phase 3
A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Bristol-Myers Squibb590 enrolled277 locationsNCT07063745
Recruiting
Phase 3
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
Chronic Inflammatory Demyelinating PolyradiculoneuropathyPolyneuropathy, Inflammatory Demyelinating, Chronic
Sanofi140 enrolled125 locationsNCT06290128
Recruiting
Phase 3
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Chronic Inflammatory Demyelinating Polyneuropathy
Sanofi160 enrolled118 locationsNCT06290141
Recruiting
Phase 1
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Renal Cell Carcinoma
Bristol-Myers Squibb125 enrolled9 locationsNCT07195682
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
Focal Segmental GlomerulosclerosisGlomerulonephritis Minimal Lesion
Sanofi84 enrolled69 locationsNCT06500702
Recruiting
Phase 3
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
Immunoglobulin G4-Related Disease
Sanofi124 enrolled68 locationsNCT07190196
Recruiting
Phase 2Phase 3
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Untreated, Unresectable, or Metastatic Colorectal Cancer
Bristol-Myers Squibb990 enrolled279 locationsNCT07221357
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Celgene960 enrolled282 locationsNCT06764485
Recruiting
Phase 2Phase 3
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Bristol-Myers Squibb690 enrolled161 locationsNCT07221149
Recruiting
Phase 2Phase 3
A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Pancreatic Ductal Adenocarcinoma
Bristol-Myers Squibb470 enrolled279 locationsNCT07076121
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Alzheimer s Disease
Bristol-Myers Squibb586 enrolled123 locationsNCT06976203
Recruiting
Phase 2
A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)
Juvenile Idiopathic Arthritis
Sanofi51 enrolled31 locationsNCT02991469
Recruiting
Phase 1
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Refractory Autoimmune Diseases
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company125 enrolled28 locationsNCT07115745
Recruiting
Phase 2
A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)
Carcinoma, Non-Small Cell Lung
Bristol-Myers Squibb130 enrolled71 locationsNCT06855771
Recruiting
Phase 3
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Non-small Cell Lung Cancer
Bristol-Myers Squibb1,000 enrolled299 locationsNCT06561386
Recruiting
Phase 2Phase 3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Breast Neoplasms
Bristol-Myers Squibb500 enrolled294 locationsNCT06926868
Recruiting
Phase 2
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Hidradenitis Suppurativa
Sanofi144 enrolled46 locationsNCT07225569
Recruiting
Phase 1
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
Rheumatoid ArthritisSystemic Lupus ErythematosusSystemic Sclerosis+1 more
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company270 enrolled54 locationsNCT05869955